These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20689121)

  • 1. Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus.
    Joffe D
    Am J Health Syst Pharm; 2010 Aug; 67(16):1326-36. PubMed ID: 20689121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.
    Seino Y; Rasmussen MF; Nishida T; Kaku K
    Curr Med Res Opin; 2010 May; 26(5):1013-22. PubMed ID: 20199137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.
    Vilsbøll T
    Expert Opin Investig Drugs; 2007 Feb; 16(2):231-7. PubMed ID: 17243943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies.
    Blonde L; Russell-Jones D
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():26-34. PubMed ID: 19878259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide in type 2 diabetes: from pharmacological development to clinical practice.
    Rossi MC; Nicolucci A
    Acta Biomed; 2009 Aug; 80(2):93-101. PubMed ID: 19848045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus.
    Drab SR
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):43S-54S. PubMed ID: 19947816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide in clinical practice: dosing, safety and efficacy.
    Peterson GE; Pollom RD
    Int J Clin Pract Suppl; 2010 Oct; (167):35-43. PubMed ID: 20949699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
    Ryan GJ; Hardy Y
    J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of liraglutide in the treatment of patients with type 2 diabetes.
    Deacon CF
    Vasc Health Risk Manag; 2009; 5(1):199-211. PubMed ID: 19436648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide: a new treatment for type 2 diabetes.
    Vilsboll T
    Drugs Today (Barc); 2009 Feb; 45(2):101-13. PubMed ID: 19343230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
    Bode B
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide: a review of its use in the management of type 2 diabetes mellitus.
    Perry CM
    Drugs; 2011 Dec; 71(17):2347-73. PubMed ID: 22085389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 analogue, in Latino/Hispanic patients with type 2 diabetes: post hoc analysis of data from four phase III trials.
    Davidson JA; Ørsted DD; Campos C
    Diabetes Obes Metab; 2016 Jul; 18(7):725-8. PubMed ID: 26936426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting.
    Kesavadev J; Shankar A; Gopalakrishnan G; Jothydev S
    Diabetes Metab Syndr; 2015; 9(1):30-3. PubMed ID: 25605673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mild renal impairment and the efficacy and safety of liraglutide.
    Davidson JA; Brett J; Falahati A; Scott D
    Endocr Pract; 2011; 17(3):345-55. PubMed ID: 21700561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Liraglutide].
    Takahashi T; Odawara M
    Nihon Rinsho; 2011 May; 69(5):883-9. PubMed ID: 21595276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus.
    Davis PN; Ndefo UA; Oliver A; Payton E
    Am J Health Syst Pharm; 2015 Jul; 72(13):1097-103. PubMed ID: 26092960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.